Finding the Proverbial Needle: Non-targeted Screening of Synthetic Opioids in Equine Plasma.

Synthetic opioids are a class of compounds that are of particular concern due to their high potency and potential health impacts. With the relentless emergence of new synthetic opioid derivatives, non-targeted screening strategies are required that do not rely on the use of library spectra or reference materials. In this study, product ion searching, and Kendrick mass defect analysis were investigated for non-targeted screening of synthetic opioids. The estimated screening cut-offs for these techniques ranged between 0.05 and 0.1 ng/mL. These techniques were designed to not be reliant on a particular vendor's software, meaning that they can be applied to existing drug screening protocols, without requiring the development and validation of new analytical procedures. The efficacy of the developed techniques was tested through blind trials, with spiked samples inserted amongst authentic plasma samples, which demonstrated the usefulness of these methods for high-throughput screening. The use of a non-targeted screening workflow that contains complementary techniques can increase the likelihood of detecting compounds of interest within a sample, as well as the confidence in detections that are made.

[1]  R. Giorgetti,et al.  Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry Assay for Quantifying Fentanyl and 22 Analogs and Metabolites in Whole Blood, Urine, and Hair , 2019, Front. Chem..

[2]  R. Smith,et al.  Characterization of 2C-phenethylamines using high-resolution mass spectrometry and Kendrick mass defect filters , 2018 .

[3]  R. Arthur,et al.  Pharmacokinetics and pharmacodynamics of butorphanol following intravenous administration to the horse. , 2013, Journal of veterinary pharmacology and therapeutics.

[4]  T. Tobin,et al.  Pharmacology of narcotic analgesics in the horse: selective blockade of narcotic-induced locomotor activity. , 1981, American journal of veterinary research.

[5]  A. Salomone,et al.  Analytical Approaches in Fatal Intoxication Cases Involving New Synthetic Opioids. , 2018, Current pharmaceutical biotechnology.

[6]  B. Thomas,et al.  Analysis of synthetic cannabinoids using high-resolution mass spectrometry and mass defect filtering: implications for nontargeted screening of designer drugs. , 2012, Analytical chemistry.

[7]  L. Sleno,et al.  The use of mass defect in modern mass spectrometry. , 2012, Journal of mass spectrometry : JMS.

[8]  R. Pacifici,et al.  New synthetic opioids in biological and non-biological matrices: A review of current analytical methods , 2018 .

[9]  K. Linnet,et al.  Application of a screening method for fentanyl and its analogues using UHPLC-QTOF-MS with data-independent acquisition (DIA) in MSE mode and retrospective analysis of authentic forensic blood samples. , 2018, Drug testing and analysis.

[10]  Lewis S. Nelson,et al.  Novel Synthetic Opioids: An Opioid Epidemic Within an Opioid Epidemic. , 2017, Annals of emergency medicine.

[11]  K. Eckart,et al.  Development of a new multi-analyte assay for the simultaneous detection of opioids in serum and other body fluids using liquid chromatography-tandem mass spectrometry. , 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[12]  K. Croes,et al.  A comprehensive LC-MS-based quantitative analysis of fentanyl-like drugs in plasma and urine. , 2010, Journal of separation science.

[13]  Lanqing Wang,et al.  Analysis of 13 fentanils, including sufentanil and carfentanil, in human urine by liquid chromatography-atmospheric-pressure ionization-tandem mass spectrometry. , 2006, Journal of analytical toxicology.

[14]  Joshua Klingberg,et al.  Collision-Induced Dissociation Studies of Synthetic Opioids for Non-targeted Analysis , 2019, Front. Chem..

[15]  R. Pacifici,et al.  Acute Intoxications and Fatalities From Illicit Fentanyl and Analogues: An Update , 2017, Therapeutic drug monitoring.

[16]  A G Marshall,et al.  Kendrick mass defect spectrum: a compact visual analysis for ultrahigh-resolution broadband mass spectra. , 2001, Analytical chemistry.

[17]  T. Tobin,et al.  Dose-related effects of fentanyl on autonomic and behavioral responses in performance horses. , 1985, General pharmacology.

[18]  Michael Thompson,et al.  Harmonized guidelines for single-laboratory validation of methods of analysis (IUPAC Technical Report) , 2002 .

[19]  Donglu Zhang,et al.  Mass defect filter technique and its applications to drug metabolite identification by high-resolution mass spectrometry. , 2009, Journal of mass spectrometry : JMS.

[20]  D. Dolinak,et al.  An LC-MS-MS Method for the Analysis of Carfentanil, 3-Methylfentanyl, 2-Furanyl Fentanyl, Acetyl Fentanyl, Fentanyl and Norfentanyl in Postmortem and Impaired-Driving Cases. , 2017, Journal of analytical toxicology.

[21]  S. Fu,et al.  Characterization of hallucinogenic phenethylamines using high-resolution mass spectrometry for non-targeted screening purposes. , 2017, Drug testing and analysis.

[22]  Herbert Oberacher,et al.  Current status of non-targeted liquid chromatography-tandem mass spectrometry in forensic toxicology , 2016 .

[23]  Adam Cawley,et al.  Current applications of high-resolution mass spectrometry for the analysis of new psychoactive substances: a critical review , 2017, Analytical and Bioanalytical Chemistry.

[24]  S. van Calenbergh,et al.  Report on a novel emerging class of highly potent benzimidazole NPS opioids. , 2019, Drug testing and analysis.

[25]  J. Holden,et al.  The endogenous opioid system and clinical pain management. , 2005, AACN clinical issues.

[26]  T. Tobin,et al.  Dose related effects of the kappa agonist U-50, 488H on behaviour, nociception and autonomic response in the horse. , 1988, Equine veterinary journal.